Clinical Trials
21 trialsNCT00600496 2026-05-27
A Phase I, Open-Label, Multi-center Study to Assess the Safety, Tolerability and Pharmacokinetics of AZD6244 (ARRY-142886)
AstraZeneca
Phase 1 Completed
NCT06632951 2025-08-11
LIVIGNO-3
AbbVie
Phase 2 Active not recruiting
NCT04306900 2025-07-29
TTX-030 in Combination With Immunotherapy and/or Chemotherapy in Subjects With Advanced Cancers
Trishula Therapeutics, Inc.
Phase 1 Completed
NCT05714553 2025-07-18
NUC-3373 in Combination With Other Agents in Patients With Advanced Solid Tumours
NuCana plc
Phase 1/2 Terminated
NCT03951831 2025-04-25
REGN2810 Followed by Chemoimmunotherapy for Newly Metastatic Hormone-sensitive Prostate Cancer
Columbia University
Phase 2 Active not recruiting
NCT02009449 2024-11-15
IVY
Eli Lilly and Company
Phase 1 Completed
NCT01957436 2024-11-12
PEACE1
UNICANCER
Phase 3 Active not recruiting
NCT03693612 2024-08-28
GSK3359609 Plus Tremelimumab for the Treatment of Advanced Solid Tumors
GlaxoSmithKline
Phase 1/2 Completed
NCT00587431 2023-11-07
Docetaxel With Rapid Hormonal Cycling as a Treatment for Patients With Prostate Cancer
Memorial Sloan Kettering Cancer Center
Phase 2 Completed
NCT00020046 2023-10-31
Docetaxel With or Without Thalidomide in Treating Patients With Metastatic Prostate Cancer
National Institutes of Health Clinical Center (CC)
Phase 2 Completed
NCT00089609 2018-04-20
Docetaxel, Thalidomide, Prednisone, and Bevacizumab to Treat Metastatic Prostate Cancer
National Institutes of Health Clinical Center (CC)
Phase 2 Completed
NCT00519285 2016-07-22
VENICE
Sanofi
Phase 3 Completed
NCT01603420 2016-03-14
External Beam Radiation With or Without Chemotherapy to Treat High Risk Prostate Cancer
Proton Collaborative Group
Phase 2/3 Terminated
NCT01685489 2015-10-27
A Phase 1b Dose Escalation Trial of PSK®/Placebo With Docetaxel to Treat Metastatic Castration-resistant Prostate Cancer
Bastyr University
Phase 1 Withdrawn
NCT00514267 2015-08-13
An Open-Label Study of YM155 + Docetaxel in Subjects With Advanced Hormone Refractory Prostate Cancer and Other Solid Tumors
Astellas Pharma Inc
Phase 1/2 Completed
NCT00808418 2014-02-03
A Study to Determine the Maximum Tolerated Dose of Elesclomol Sodium Given With a Fixed Dose of Docetaxel and Prednisone in Patients With Metastatic Prostate Cancer
Synta Pharmaceuticals Corp.
Phase 1 Completed
NCT01604863 2012-11-01
A Study of HGS1036 in Combination With Chemotherapy in Subjects With Advanced Solid Malignancies
GlaxoSmithKline
Phase 1 Suspended
NCT00031187 2011-10-24
Study of SGN-15, Antibody-Drug Conjugate, to Treat Hormone Refractory Prostate Cancer
Seagen Inc.
Phase 2 Completed
NCT00049296 2010-06-11
Thalidomide and Docetaxel in Treating Patients With Advanced Cancer
Case Comprehensive Cancer Center
Phase 1 Completed
NCT00089856 2008-11-05
GVAX® Vaccine for Prostate Cancer vs Docetaxel & Prednisone in Patients With Metastatic Hormone-Refractory Prostate Cancer
Cell Genesys
Phase 3 Terminated
NCT00133224 2008-09-23
Docetaxel in Combination With GVAX ® Immunotherapy Versus Docetaxel and Prednisone in Prostate Cancer Patients
Cell Genesys
Phase 3 Terminated